Lenalidomide Capsule
Product Images NDC 69097-382

15 FDA label images from Cipla Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 69097-382). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 01)

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 01)
Chemical structure of lenalidomide, showing its molecular framework including a fused bicyclic ring system with amino and keto functional groups.*
FDA Label Image

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 02)

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 02)
A Kaplan-Meier survival curve chart comparing progression-free survival probabilities over months for three treatment groups labeled Rd Continuous, Rd18, and MPT. The y-axis shows survival probability percentage, and the x-axis shows time in months. The chart includes confidence intervals around survival estimates, a log-rank p-value, and a table of the number of subjects at risk at various time points for each group.*
FDA Label Image

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 03)

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 03)
A survival probability Kaplan-Meier curve chart comparing overall survival rates over time in months for three groups labeled Rd Continuous, Rd R18, and MPT. The y-axis represents survival probability percentage, and the x-axis shows overall survival in months up to 72. The chart includes a table beneath showing the number of subjects at risk at various time points and hazard ratios (HR) with confidence intervals (CI) for comparisons between groups.*
FDA Label Image

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 04)

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 04)
A Kaplan-Meier survival curve chart depicting progression-free survival (months) for two groups: Lenalidomide (blue solid line) and Placebo (red dashed line). It includes a table below showing the number of subjects at risk over time and notes on hazard ratio and median survival times with confidence intervals.*
FDA Label Image

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 05)

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 05)
A Kaplan-Meier survival curve chart comparing progression-free survival over time (in months) between two groups: lenalidomide and placebo. The y-axis represents survival probability, while the x-axis shows progression-free survival in months. The chart includes numbers of subjects at risk over time and reports a hazard ratio with confidence intervals.*
FDA Label Image

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 06)

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 06)
A Kaplan-Meier survival curve chart comparing the proportion of subjects over time to progression (months) for two groups: Lenalidomide/Dex and Placebo/Dex. The vertical axis shows the proportion of subjects, and the horizontal axis shows time in months. The chart includes a hazard ratio (HR) with 95% confidence interval and a statistically significant p-value.*
FDA Label Image

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 07)

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 07)
A Kaplan-Meier survival curve chart showing the proportion of subjects over time to progression in months. It compares two groups: Lenalidomide/Dex (blue line) and Placebo/Dex (black/red line), illustrating time to progression and hazard ratio with confidence interval.*
FDA Label Image

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 08)

Image (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 08)
Kaplan-Meier survival curve chart depicting progression-free survival probability over time in months. The graph compares two groups: patients treated with Rituximab plus Lenalidomide versus patients treated with Rituximab plus Placebo. The x-axis represents progression-free survival in months, and the y-axis shows survival probability. Below the chart, the number of subjects at risk is tabulated for each group at different time points.*
FDA Label Image

Container-5mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 09)

Container-5mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 09)
Label for lenalidomide capsules 5 mg by Cipla USA Inc. The label includes a prominent warning about potential human birth defects and instructions for pharmacists to dispense the medication guide. It lists 28 capsules in the package and states the medication is Rx only. The label also shows storage instructions, manufacturer information for Cipla Ltd. in Canada, and a barcode.*
FDA Label Image

Container-10mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 10)

Container-10mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 10)
Label for Lenalidomide Capsules 10 mg by Cipla USA Inc. The label displays the product name, strength (10 mg), and quantity (28 capsules). It includes a warning about potential human birth defects and storage instructions. The label indicates manufacture by Cipla Ltd. and Cipla USA Inc., with a barcode on the right side.*
FDA Label Image

Container-15mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 11)

Container-15mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 11)
Label for Lenalidomide capsules 15 mg by Cipla USA Inc. The label displays the dosage strength (15 mg) prominently in an orange box. It includes a warning for potential human birth defects and instructions for pharmacists to dispense a medication guide. The label specifies the manufacturer as Cipla Ltd. and Cipla USA, Inc. It also provides storage instructions and contains a barcode on the right side.*
FDA Label Image

Container-20mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 12)

Container-20mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 12)
Label for Lenalidomide Capsules 20 mg by Cipla USA Inc. The label includes the drug name and dosage strength prominently in black and green text. It contains a warning about potential human birth defects and instructs pharmacists to dispense the medication guide. The label also lists manufacturing details including Cipla Ltd. and Cipla USA Inc. addresses, storage instructions, and a barcode.*
FDA Label Image

Container-25mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 13)

Container-25mg-genvion (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 13)
This is a label for lenalidomide capsules, 25 mg strength, manufactured by Cipla Ltd. and labeled by Cipla USA Inc. The label includes a warning about potential human birth defects and instructs pharmacists to provide a medication guide. It indicates a count of 21 capsules and provides storage instructions and manufacturing details. The label features a barcode and uses Pantone colors 2945 C, 2597 C, and Black C.*
FDA Label Image

Container-5mg-aizant (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 14)

Container-5mg-aizant (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 14)
Label for lenalidomide capsules, 5 mg strength, by Cipla USA Inc. The label indicates a quantity of 28 capsules and includes warnings about potential human birth defects. It has storage instructions and manufacturer details, with a barcode and a blank area for batch information overprinting during commercial packing.*
FDA Label Image

Container-10mg-aizant (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 15)

Container-10mg-aizant (Eeb99fdb 805d 41fb 981e Ec8a442f4e82 15)
Label for Lenalidomide 10 mg capsules by Cipla USA Inc. The label shows the drug name, dosage strength, and a warning about potential human birth defects. It includes storage instructions, manufacturer details, a barcode, and a note for pharmacists to dispense the Medication Guide. The label indicates a package size of 28 capsules and features space for batch overprinting with serial number, expiry, and lot information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.